PROGRAM

2nd International Conference “Translational Research in Oncology: a New Approach to Personalized Medicine”

May 8, 2012IRCCS IRST, Meldola

May 9 - 10 - 11, 2012HoTel GlobuS CITy, FoRlì

Alto Patronato del Presidente della Repubblica ItalianaMinistero della Salute

Ministero dell’Istruzione, dell’Università e della Ricerca

Regione Emilia RomagnaProvincia Forlì-Cesena

Comune di Forlì

Ordine dei Medici e Odontoiatri Forlì-CesenaAzienda Unità Sanitaria Locale di Forlì

AIOM, Associazione Italiana di Oncologia MedicaAIRO, Associazione Italiana di Radioterapia Oncologica

ESMO, European Society for Medical OncologyFISM, Federazione delle Società Medico-Scientifiche Italiane

IOR, Istituto Oncologico RomagnoloISO, Società Italiana di Osteoncologia

LILT, Lega Italiana per la Lotta contro i TumoriSIC, Società Italiana di Cancerologia

SIE, Società Italiana di Ematologia

Under the Auspices of:

3

Scientific Secretariat IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)Via Maroncelli, 4047014 Meldola (FC), ItalyPh. +39 0543 739254 - 51ufficio.formazione@irst.emr.itwww.irst.emr.it

Organizing SecretariatStudio E.R. Congressi - Triumph GroupVia Marconi, 36 40122 Bologna, ItalyPh. +39 051 4210559 Fax +39 051 4210174ercongressi@triumphgroup.it www.ercongressi.it

Scientific Committee

Giovanni Luca Frassineti Giorgio CrucianiUgo De GiorgiMuller FabbriPier Paolo FattoriGiampaolo GavelliToni IbrahimCarlo MilandriOriana NanniGiovanni PaganelliRolando PolicoAlberto RavaioliRuggero RidolfiAndrea RoccaWainer Zoli

3

Organizing Committee

Carlo Milandri Salvatore Luca BurgioAlberto FarolfiAndrea Casadei GardiniTalia PiolantiMarianna RicciGráinne TierneyMartina Valgiusti Annalisa Volpi

Presidents

Dino AmadoriRosella Silvestrini

4

FACULTY

4

Matti S. Aapro Genolier, SwitzerlandAdriana Albini Milano, ItalyDino Amadori Meldola (FC), ItalyAndrea Ardizzoni Parma, ItalyPaolo A. Ascierto Napoli, ItalyDomenico Barone Meldola (FC), ItalyMirco Bartolomei Cesena, ItalyMassimo Bellomi Milano, ItalyMarcello Benassi Meldola (FC), ItalyGiampaolo Biti Firenze, ItalySergio Bracarda Arezzo, ItalyPaolo Bruzzi Genova, ItalyGeorge A. Calin Houston, USAStefano Cascinu Ancona, ItalyIan Chau London, United KindomRita Chiari Perugia, ItalyPierfranco Conte Modena, ItalyMassimo Cristofanilli Philadelphia, USACarlo M. Croce Columbus, USAGiorgio Cruciani Ravenna, ItalyRiccardo Dalla Favera New York, USARomano Danesi Pisa, ItalySerena Di Cosimo Milano, ItalyUgo De Giorgi Meldola (FC), ItalyAntonio Esposito Milano, ItalyMuller Fabbri Meldola (FC), Italy - Columbus, USAPier Paolo Fattori Meldola (FC), ItalyRoberto Foà Roma, ItalySilvia C. Formenti New York, USAG. Luca Frassineti Meldola (FC), ItalyGianluca Gaidano Novara, Italy Ramiro Garzon Columbus, USAGiampaolo Gavelli Meldola (FC), ItalyEmanuele Giordano Bologna, ItalyGrazia Graziani Roma, ItalyToni Ibrahim Meldola (FC), ItalyYibin Kang Princeton, USAClaus-Henning Köhne Oldenburg, GermanyBarbara Kopf Meldola (FC), ItalyEunice L. Kwak Boston, USA

FACULTY

55

Roberto Labianca Bergamo, ItalyJames Larkin London, United KindomMichele Maio Siena, ItalyGiovanni Mandoliti Rovigo, ItalyFrancesco M. Marincola Bethesda, USAMassimo Massaia Torino, ItalyLaura Mercatali Meldola (FC), ItalyCarlo Milandri Empoli, ItalyAlessandro Morabito Napoli, ItalyDario Neri Zürich, SwitzerlandGiovanni Paganelli Milano, ItalyAngelo Paradiso Bari, ItalyFabrizio Pane Napoli, ItalyPier Giuseppe Pelicci Milano, ItalyEdith Perez Jacksonville, USASandro Pignata Napoli, ItalyRolando Polico Meldola (FC), ItalyPaolo Pronzato Genova, ItalyAlberto Ravaioli Rimini, ItalyFederico Rea Padova, ItalyRuggero Ridolfi Meldola (FC), ItalyAndrea Rocca Meldola (FC), ItalyRoberto Sabbatini Modena, ItalyGiuseppe Saglio Orbassano (TO), ItalyLeonardo Santi Genova, ItalyAnna Sarnelli Meldola (FC), ItalyGiorgio V. Scagliotti Torino, ItalyManuela Schmidinger Wien, AustriaGianluca Severi Carlton, AustraliaStefano Severi Meldola (FC), ItalyRosella Silvestrini Meldola (FC), ItalyAlberto Sobrero Genova, ItalyCora Sternberg Roma, ItalyStefano Tamberi Faenza (RA), ItalyAyalew Tefferi Rochester, USAAnna Tesei Meldola (FC), ItalyGabri van der Pluijm Leiden, The NetherlandsAugusto Villanueva Barcelona, SpainJeffrey Weber Tampa, USAKurt Zatloukal Graz, AustriaPier Luigi Zinzani Bologna, Italy

6

PROGRAM

6

Tuesday May 8, 2012

2.30 p.m. Welcome Ceremony D. Amadori, Scientific Director IRCCS IRST R. Silvestrini, Scientific Consultant IRCCS IRST

AIOM President S. Cascinu “In memory of Marco Venturini” AIRO President G. Mandoliti ISO President T. Ibrahim SIE President F. Pane

President: L. SantiChairmen: A. Paradiso, A. Ravaioli

3.30 p.m. Lecture Clinical traslational research in oncology:

trials methodology and new developments P. Bruzzi 4.00 p.m. Lecture Circulating Tumor Cells: preclinical data and clinical impact M. Cristofanilli

4.30 p.m. Lecture Mammary epithelial lineage determinants in mammary

gland development, breast cancer initiation and metastasis Y. Kang

5.00 p.m. Lecture Epidemiological research in the whole-genome era:

challenges and opportunities G. Severi

5.30 p.m. Lecture Bioengineering as a tool for translational research in

oncology E. Giordano

6.00 p.m. Opening Ceremony with the Italian Minister of Health7.00 p.m. Visit of the Institute

7.30 p.m. Cocktail

IRCCS IRST, Meldola

7

PROGRAM

7

Wednesday May 9, 2012 Hotel Globus City, Forlì

8.30 a.m. Lecture The role of biobanking in personalized medicine K. Zatloukal

Breast President: A. Rocca Chairmen: G. Cruciani, P. Pronzato

9.00 a.m. Targeting breast cancer stem cells P.G. Pelicci

9.25 a.m. Targeting the PI3K/Akt/mTOR pathway in breast cancer S. Di Cosimo

9.50 a.m. New therapeutic opportunities in HER2-positive tumors E. Perez

10.15 a.m. Coffee break

10.30 a.m. Synthetic lethal approaches: PARP inhibitors G. Graziani

10.55 a.m. Anti-angiogenic therapies in breast cancer R. Danesi

11.20 a.m. New therapeutic opportunities in breast cancer: from liposomal to nanotechnological formulations

P. Pronzato

11.45 a.m. The role of microenvironment in breast cancer development and progression

A. Albini

12.10 p.m. Discussion

8

PROGRAM

8

Radiometabolic Medicine President: G. PaganelliChairmen: M. Bartolomei, S. Severi

12.45 p.m. Monoclonal antibody small immunoprotein (SIP) tumor targeting in patients with cancer

D. Neri

1.10 p.m. Poster Session and Buffet Lunch Chairmen: G.L. Frassineti, W. Zoli

P01Fenretinide: new perspectives in treatment of medulloblastoma Bartolini D., Magnani E., Pagani A., Focaccetti C., Cantelmo A.R., Albini A.Fondazione MultiMedica Onlus, Science and Technology Pole, Milan; IRCCS MultiMedica, Milan, Italy

P02Isolation of living circulating tumor cells using the DEPArrayTM platformCarloni S., Fanini F., Gallerani G., Bandini E., Pignatta S., Fabbri F., Brigliadori G., Amadori D., Zoli W.Biosciences Laboratory, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Mel-dola (FC), Italy

P03I.R.S.T.’s surveillance of therapeutic use of investigational medicinal product’s under Italian Ministerial Decree 8 May 2003 (D.M. 08/05/2003): possible tool to generate translational research’s hypothesisDonati C., Burioli P., Benini G., Minguzzi M.Clinical Oncological Pharmacy and Ethics Committee’s (CEAV/IRST), Scientific Secretariat of IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola (FC), Italy

P04Investigation of circulating colon and lung cancer cells using dielectrophoresis-based instrumentationFabbri F., Carloni S., Ulivi P., Gallerani G., Fici P., Chiadini E., Amadori D., Zoli W. Biosciences Laboratory, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola (FC), Italy

P05BRAF gene mutation and MLH1 promoter methylation in colorectal carcinomas with microsatellite instability and loss of MLH1 protein expressionGafà R., Maestri I., Ulazzi L., Mazzoni R., Mora F., Magri E., Zampini C., Lanza G.Section of Anatomic Pathology, Department of Experimental and Diagnostic Medicine, University of Ferrara, Ferrara, Italy

9

P06Developing of an in vitro model of breast cancer osteolytic bone metastasis for precli-nical trials of novel bone-targeted molecules Liverani C., Ibrahim T., Mercatali L., Zoli W., Amadori D.Osteoncology Center, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola (FC), Italy

P07Phosphorylated Akt and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan- cetuximabLoretelli C., Giampieri R., Scartozzi M., Maccaroni E., Mandolesi A., Biagetti S., Alfonsi S., Giustizi L., Faloppi L., Bittoni A., Bianconi M., Del Prete M., Bearzi I., Cascinu S.Clinica di Oncologia Medica, AO Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in Oncologia, Università Politecnica delle Marche, Ancona, Italy; Anatomia Patologica, Università Politecnica delle Marche, Ancona, Italy; Oncologia Medica, Ospedale di Fermo, Fermo, Italy

P08Highly sensitive FRET biosensors for detecting MT1-MMP activity in live breast cancer cellsLu S., Wang Y., Huang H., Wang Y., Pan Y., Strongin A.Y., Chaney E., Boppart S.A., Ozer H.University of Illinois Cancer Center, Chicago, USA

P09Molecular characterization of breast cancer cell lines after zoledronic acid treatmentMercatali L., Ibrahim T.,Liverani C., Guerra D., Zoli W., Amadori D.Osteoncology Center, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola (FC), Italy

P10Mini-gene profiling for the prediction of metastatization to bone in breast cancer patientsMercatali L., Ibrahim T., Liverani C., Guerra D., Scarpi E., Zoli W., Amadori D.Osteoncology Center, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola (FC), Italy

P11Osteoncology Center: the management of patients with bone cancer disease in a mul-tidisciplinary approachNicoletti S., Ibrahim T., Ricci M., Ricci R., Fabbri L., Falasconi M.C., Casadei R., Micheletti S., Oboldi D., Severi S., Amadori E., Galassi R., Matteucci F., Moretti A., Sansovini M., Petrella E., Ceccolini M., Gavelli G.P., Riva N., Calpona S., Mercatali L., Liverani C., Serra P., Monti M., Maltoni M., Amadori D.Osteoncology Center, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola (FC), Italy

9

10

PROGRAM

10

P12MicroRNA profile in osteosarcoma: role of miR-1 and miR-133bNovello C., Pazzaglia L., Cingolani C., Conti A., Quattrini I., Manara M.C., Picci P., Benassi M.S.Laboratory of Experimental Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy

P13Circulating RANK/RANK-L/OPG pathway in cancer patients treated with Zoledronic AcidRicci M., Ibrahim T., Mercatali L., Scarpi E., Fabbri F., Liverani C., Serra P., Ricci R., Nicoletti S., Zoli W., Amadori D.Osteoncology Center, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola (FC), Italy

P14The role of Research Nurse in the management of bone cancer patients in the multidisci-plinary Osteoncology Center (CDO)Ricci R., Ibrahim T., Zavoiu V., Resta D., Tedaldi R., Mercatali L., Nicoletti S., Amadori D.Osteoncology Center, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola (FC), Italy

P15Circulating tumour cells from bench to bed: streamlining from technological research to clinical practiceTorchio M., Danova M., Mazzini G.S.C. Medicina Interna e Oncologia Medica, A.O. di Pavia, Ospedale di Vigevano, Italy; Istituto di Genetica Molecolare GM-CNR, Pavia, Italy

P16EGFR and K-RAS analysis in cytological specimens from Non Small Cell Lung Cancer (NSCLC) patientsUlivi P., Zoli W., Chiadini E., Capelli L., Candoli P., Calistri D., Silvestrini R., Puccetti M.Biosciences Laboratory, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumo-ri (IRST), Meldola (FC), Italy; Pneumology Unit, Lugo Hospital, Lugo, Italy; Pathology Unit, S. Maria delle Croci Hospital, Ravenna, Italy

P17Multiple marker detection in peripheral blood for NSCLC diagnosisUlivi P., Mercatali L., Casoni G.L., Scarpi E., Bucchi L., Silvestrini R., Sanna S., Monteverde M., Zoli W., Poletti V., Amadori D.IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola (FC), Italy; Interventional Pulmonology and General Thoracic Surgery, Department of Thoracic Diseases, Mor-gagni-Pierantoni Hospital, Forlì, Italy

11

PROGRAM

11

Osteoncology President: P. ConteChairmen: T. Ibrahim, L. Mercatali

2.30 p.m. Lecture Novel mediators of tumor-stromal interactions

in bone metastasis Y. Kang

3.00 p.m. Osteoclast-dependent and -independent effects of RANKL inhibition on tumorogenesis and metastasis

G. van der Pluijm

3.25 p.m. Beyond the bone: multitarget approach with zoledronic acid

M. Massaia

3.50 p.m. Prevention of bone metastases: clinical data M.S. Aapro

4.15 p.m. Discussion

miRNA President: M. FabbriChairmen: G.A. Calin, C.M. Croce

4.30 p.m. Lecture Causes and consequences of miRNA deregulation in cancer

C.M. Croce

5.00 p.m. microRNAs in hematological malignancies R. Garzon

5.25 p.m. microRNAs in solid tumors M. Fabbri

12

PROGRAM

12

5.50 p.m. Non-coding RNAs and cancer: beyond microRNAs G.A. Calin

6.15 p.m. Discussion

Thursday May 10, 2012 Hotel Globus City, Forlì

Gastrointestinal tract and liver President: G.L. FrassinetiChairmen: S. Cascinu, R. Labianca

9.00 a.m. Lecture Current and emerging therapies for metastatic colorectal cancer

A. Sobrero

9.30 a.m. Adjuvant chemotherapy and targeted therapies for resected colon cancer. What next?

C.H. Köhne

9.55 a.m. Advanced gastric cancer: the role of target therapy I. Chau

10.20 a.m. Linking signalling pathways and molecular therapies in hepatocellular carcinoma

A. Villanueva

10.45 a.m. Discussion

11.00 a.m. Coffee break

Hematology President: P.P. FattoriChairmen: R. Foà, P.L. Zinzani

11.30 a.m. Lecture Analysis of the genome of Diffuse Large B-cell Lymphoma: pathogenetic and clinical implications

R. Dalla Favera

13

PROGRAM

12.00 p.m. Targeting “JAK” in myeloproliferative neoplasms

A. Tefferi

12.25 p.m. Tyrosine kinase pathways in hematologic disorders

G. Saglio

12.50 p.m. Chemorefractoriness in B cell Malignancies: Who and Why

G. Gaidano

1.15 p.m. Discussion

1.30 p.m. Poster Session and Buffet Lunch Chairmen: G.L. Frassineti, W. ZoliP18Slug silencing increases radiosensitivity of melanoma cells in vitroArienti C., Tesei A., Carloni S., Ulivi P., Romeo A., Ghigi G., Menghi E., Sarnelli A., Parisi E., Silvestrini R., Zoli W.Biosciences Laboratory, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola (FC), Italy; Radiotherapy Department, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola (FC), Italy; Department of Health Physics, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola (FC), ItalyP19Cancer region detection by visual features in histopathologyBevilacqua A., Gherardi A., Busa C., Bravaccini S.DEIS, Department of Electronics, Computer Science and Systems, University of Bologna, Italy; ARCES, Advanced Research Center on Electronic Systems, University of Bologna, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola (FC), ItalyP20Extension of the microscope’s depth of focusBevilacqua A., Zoli W., Piccinini F., Tesei A.DEIS, Department of Electronics, Computer Science and Systems, University of Bologna, Italy; ARCES, Advanced Research Center on Electronic Systems, University of Bologna, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola (FC), ItalyP21Assessing reliability in computation of perfusion CT indexesBevilacqua A., Barone D., Carozza L., Gavelli G.DEIS, Department of Electronics, Computer Science and Systems, University of Bologna, Italy; ARCES, Advanced Research Center on Electronic Systems, University of Bologna, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola (FC), Italy

13

14

PROGRAM

14

P22Detecting early errors in DCE-CT imagingBevilacqua A., Barone D., Carozza L., Gavelli G.DEIS, Department of Electronics, Computer Science and Systems, University of Bologna, Italy; ARCES, Advanced Research Center on Electronic Systems, University of Bologna, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola (FC), Italy

P23Role of telomerase activity in predicting the clinical outcome of patients with benign lesions of the uterine cervix or CIN Bravaccini S., Amadori A., Scarpi E., Tumedei M.M., Puccetti M., Zoli W., Silvestrini R. IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola (FC), Italy; Department of Obstetrics and Gynecology, Morgagni-Pierantoni Hospital, Forlì, Italy

P24Feasibility study of translational research in Africa: preliminary data on the biology of 71 breast cancer cases from Bugando Medical Center Bravaccini S., Serra P., Tumedei M.M., Puccetti M., Rengucci C., Masalu N., Zoli W., Crinò L., Puglisi F., Franciosi V., Serra L., Amadori D.IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola (FC), Italy; Bu-gando Medical Center, Mwanza, Tanzania; Medical Oncology Department, S. Maria della Misericordia Hospital, Perugia, Italy; Department of Oncology, University Hospital of Udine, Udine, Italy; Medical Oncology Unit, University-Hospital of Parma, Parma, Italy; Pathology Unit, Morgagni-Pierantoni Ho-spital, Forlì, Italy

P25Protective effect of Rosiglitazone on late pulmonary damage and radiation-induced acute intestinal damage on a murine modelCassani S., Mangoni M., Franzese C., Masoni T., Loi M., Gerini C., Sottili M., Vanzi E., Pupi A., Livi L., Biti G.P.Clinical Physiopathology Department, University of Florence, Firenze, Italy

P26Prognostic value of proliferation marker Ki67 in advanced breast cancerFarolfi A., Ibrahim T., Mercatali L., Scarpi E., Ricci R., Ricci M., Liverani C., Guerra D., Serra P., Nanni O., Amadori D. Osteoncology Center, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola (FC), Italy

P27Hormone receptor, Her-2 and Ki67 discordance between primary breast cancer and paired metastases: clinical impactFarolfi A., Ibrahim T., Mercatali L., Scarpi E., Ricci R., Ricci M., Liverani C., Guerra D., Serra P., Nanni O., Amadori D.

15 15

PROGRAM

Osteoncology Center, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola (FC), Italy

P28Local antitumor immune responses in tumor tissues after vaccination with dendritic cell (DC) vaccine in patients with advanced melanomaGranato A.M., Ancarani V., Petrini M., Fiammenghi L., Pancisi E., Ridolfi L., Nicoletti S., Serra L., Lanza G., Verdecchia G.M., Riccobon A., Amadori D., Ridolfi R., Guidoboni M.Immunotherapy, Department of Medical Oncology, IRCCS Istituto Scientifico Romagnolo per lo Stu-dio e la Cura dei Tumori (IRST) (FC) Italy; Department of Pathology, Oncological Surgery, Morgagni-Pierantoni Hospital, Forlì, Italy; Department of Pathology, Ferrara University, Ferrara, Italy

P29The Abs.I.De. (Abscopal Effect, Interferon-alpha, Dendritic Cell Vaccine) study: a ran-domized phase II “Proof of Concept” clinical study in Advanced MelanomaGuidoboni M., Ridolfi L., Nicoletti S.L.V., Petrini M., Fiammenghi L., Granato A.M., Ancarani V., Pancisi E., Soldati V., Valmorri L., Imbalzano S., Nanni O., Polico R., Amadori D., Riccobon A., Ridolfi R.Immunotherapy, Unit of Biostatistics and Clinical Trials, Radiotherapy and Department of Medical Oncology, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola (FC), Italy

P30Antitumor activity of Zoledronic Acid in combination with Cisplatin in triple negative breast cancer cell linesLiverani C., Ibrahim T., Mercatali L., Ciani S., Fabbri F., Zanoni M., Zoli W., Amadori D.Osteoncology Center, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola (FC), Italy

P31Specific biomarkers are associated to docetaxel and gemcitabine resistant NSCLC cell linesPasini A., Paganelli G., Tesei A., Zoli W., Giordano E., Calistri D.Laboratory of Cellular and Molecular Engineering “S. Cavalcanti”, School of Biomedical Engineering University of Bologna, Campus of Cesena, Cesena (FC), Italy; Biosciences Laboratory, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola (FC), Italy

P32Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with High-dose Interleukin-2 (HD-IL-2)Ridolfi L., Guidoboni M., Nicoletti S.V.L., Romeo A., Ghigi G., Parisi E., Polico R., Petrini M., Fiammenghi L., Granato A.M., Ancarani V., Pancisi E., Soldati V., Valmorri L., Imbalzano S., Riccobon A., Ridolfi R.Immunotherapy, Radiotherapy, Unit of Biostatistics and Clinical Trials, IRCCS Istituto Scientifico Roma-gnolo per lo Studio e la Cura dei Tumori (IRST), Meldola (FC), Italy

1616

PROGRAM

P33The therapeutic activity of gemcitabine on transplanted intracranially Ehrlich tumor in miceStukov A.N., Gershanovich M.L., Filatova L.V., Semiglazova T.J., Tarasenkova A.A., Latipova D.Kh., Vershinina S.F., Belyaeva O.A., Brezhnev N.V., Moiseyenko F.V., Chubenko V.A.FGBU Research Institute of Oncology named after N.N. Petrov, Saint-Petersburg, Russia

Radiotherapy President: R. PolicoChairmen: G. Biti, R. Silvestrini

2.30 p.m. Lecture Radiobiology from the physician’s point of view

S.C. Formenti

3.00 p.m. Radiobiology from the physicist’s point of view M. Benassi, A. Sarnelli

3.25 p.m. Creation of a radiobiology laboratory at IRCCS IRST A. Tesei

3.50 p.m. Discussion

Prostate and KidneyPresident: U. De Giorgi Chairmen: R. Sabbatini, C. Sternberg

Prostate cancer:

4.00 p.m. Emerging drugs for the pre-docetaxel space S. Bracarda

4.25 p.m. Which treatment after docetaxel for castration- resistant prostate cancer?

C. Sternberg

Kidney cancer:

4.50 p.m. Best standard for front-line therapy in metastatic renal cell cancer

M. Schmidinger

17

PROGRAM

17

5.15 p.m. How to select drugs for TKI resistant metastatic renal cell cancer

J. Larkin

5.40 p.m. Discussion

Ovarian cancer:Chairmen: B. Kopf, S. Tamberi

6.00 p.m. Lecture Effect of antiangiogenic drugs in ovarian cancer

S. Pignata

Friday May 11, 2012 Hotel Globus City, Forlì

Radiology President: G. Gavelli

Chairmen: D. Barone, G. Gavelli

8.30 a.m. Imaging of perfusion of solid-body tumors (CT and MR)

M. Bellomi

8.55 a.m. Quantitative vascular measurements with imaging A. Esposito

9.20 a.m. Discussion

LungPresident: C. Milandri Chairmen: A. Morabito, F. Rea

9.30 a.m. Folate pathway: a special target for chemotherapy? G.V. Scagliotti

9.55 a.m. EGFR inhibitors A. Ardizzoni

1818

10.20 a.m. Anti-angiogenetics R. Chiari

10.45 a.m. EML4_ALK target E.L. Kwak

11.10 a.m. Discussion

Immunotherapy President: R. RidolfiChairmen: P.A. Ascierto, M. Maio

11.30 a.m. Lecture Target therapies in melanoma J. Weber

12.00 p.m. Gene-expression profiling in vaccine therapy and immunotherapy for cancer

F.M. Marincola

12.25 p.m. Discussion

12.30 p.m. Conclusions and Closing Remarks D. Amadori, R. Silvestrini 1.00 p.m. Lunch

19

GENERAL INFORMATION

Meeting venues May 8, 2012IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)Via Maroncelli, 40 - 47014 Meldola (FC), ItalyPh. +39 0543 739254 - 51ufficio.formazione@irst.emr.itwww.irst.emr.it

How to reach the meeting venues

IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), MeldolaA shuttle service from Hotel Globus City to Meldola and back will be provided according to the meeting timetable. Please contact the Organizing Secretariat for further information.

Hotel Globus City, ForlìBy plane: Bologna G. Marconi Airport, 70 km.By car: A14 Bologna-Taranto Motorway, exit “Forlì”, 500 m. Free parking.By train: Forlì train station, 2 km.

19

May 9-10-11, 2012Hotel Globus City Via Traiano Imperatore, 4 47122 Forlì, Italy Ph. +39 0543 722215 hotelglobuscity.com

2020

GENERAL INFORMATION

LanguageThe Conference will be in English with no simultaneous translation into other languages.

BadgeAll registered participants, speakers and exhibitors will be given a badge which they must wear to be admitted to the scientific sessions.

Attendance certificateA certificate will be given to all participants at the end of the Conference.

Italian CME creditsTwo requests for Italian CME credits have been made for physicians, biologists, technicians,pharmacists, nurses and physicists.

The Italian Ministry of Health allows: • 5.5 CME credits for May 8-9, 2012 • 6 CME credits for May 10-11, 2012

At the registration desk attendees will receive two different evaluation forms related to each request.

ESMO-MORA pointsThe conference has been awarded the ESMO Label with: 8 ESMO-MORA cat. 1 points.

Registration Fees (inclusive of VAT)AIOM members Euro 100ESMO members Euro 100ISO members Euro 100Participants under 35 years Euro 100Others Euro 200

The registration fees include: participation in the scientific sessions, access to exhibition area, attendance certificate, Conference proceedings dvd, lunches, coffee breaks and welcome cocktail.

How to registerThe completed registration form (also available on line at http://www.sictro2012.com/doc/registration.pdf) and payment must be sent by fax to: +39 051 4210174. Registration can only be accepted and confirmed when the registration form and payment have been received by the Organizing Secretariat Studio E.R. Congressi.

21

GENERAL INFORMATION

21

SlidesSlides must be in English. Computer videoprojection will be available in a Microsoft Power Point™ extension. Other requirements should be communicated to the Organizing Secretariat as soon as possible. Slides should be handed to the slide center one hour before the beginning of the session.

Hotel Booking and Travel AgencyParticipants are kindly requested to contact the Hotel Booking and Travel Agency, Bononia Viaggi, in order to arrange their accomodation in Italy.Bononia ViaggiPiazza dei Martiri, 1 - 40121 Bologna - ItalyPh. +39 051 4211585 - Fax +39 051 249846paola.libbra@bononiaviaggi.it - www.bononiaviaggi.it

ChangesParts of the program may be changed if and when necessary without notice.

22 22

ACKNOWLEDGMENTSNOTES

AcknowledgementsNOVARTIS

ROCHE

AMGEN DOMPéASTELLAS PHARMA

ASTRAZENECABRISTOL MYERS SQUIBB

ELI LILLY ITALIAJANSSEN

PFIZER ITALIATEVA ITALIA

BAYER SCHERING PHARMACELGENE

SANOFI-AVENTIS

EISAIGLAXOSMITHKLINE

IPSENITALFARMACO

MERCK SERONOSANDOZ BIOPHARMACEUTICALS

22

AcknowledgementsNOVARTIS

ROCHE

AMGEN DOMPéASTELLAS PHARMA

ASTRAZENECABRISTOL MYERS SQUIBB

ELI LILLY ITALIAJANSSEN

PFIZER ITALIATEVA ITALIA

BAYER SCHERING PHARMACELGENE

SANOFI-AVENTIS

EISAIGLAXOSMITHKLINE

IPSENITALFARMACO

MERCK SERONOSANDOZ BIOPHARMACEUTICALS

Organizing SecretariatStudio E.R. Congressi - Triumph GroupVia Marconi, 36 40122 Bologna, ItalyPh. +39 051 4210559 Fax +39 051 4210174ercongressi@triumphgroup.it www.ercongressi.it

Scientific SecretariatIRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)Via Maroncelli, 4047014 Meldola (FC), ItalyPh. +39 0543 739254 - 51ufficio.formazione@irst.emr.itwww.irst.emr.it

Guido Cagnacci, Ratto di Europa (1644/45 ca.) - Collezione Molinari Pradelli, Bologna

www.sictro2012.com